Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAN | American Academy of Neurology |
| AChR | Acetylcholine receptor |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| BCMA | B-cell maturation antigen |
| BLA | Biologics license application |
| C5 | Complement component 5 |
| CAR | Chimeric antigen receptor |
| CAR-T | Chimeric antigen receptor T-cell (therapy) |
| CD | Cluster of differentiation |
| cGMP | Current good manufacturing practice |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CRS | Cytokine release syndrome |
| DNA | Deoxyribonucleic acid |
| DRG | Diagnosis-related group |
| EBMT | European Society for Blood and Marrow Transplantation |
| EQ-5D-5L | EuroQol 5-dimension, 5-level questionnaire |
| evLYG | Equal value of life-years gained |
| FcRn | Neonatal Fc receptor |
| FDA | U.S. Food and Drug Administration |
| FY | Fiscal year |
| G-CSF | Granulocyte colony-stimulating factor |
| gMG | Generalized myasthenia gravis |
| HIV | Human immunodeficiency virus |
| HSV | Herpes simplex virus |
| ICAHT | Immune effector cell-associated hematotoxicity |
| ICANS | Immune effector cell-associated neurotoxicity syndrome |
| ICER | Institute for Clinical and Economic Review |
| IgG | Immunoglobulin G |
| IRR | Infusion-related reaction |
| ITT | Intention-to-treat |
| IV | Intravenous |
| IVIg | Intravenous immunoglobulin |
| JACIE | Joint Accreditation Committee of ISCT and EBMT |
| JAK | Janus kinase |
| JDM | Juvenile dermatomyositis |
| LRP4 | Low-density lipoprotein receptor-related protein 4 |
| MG | Myasthenia gravis |
| MG-ADL | Myasthenia Gravis Activities of Daily Living |
| MG-QoL-15r | Myasthenia Gravis Quality of Life 15-item revised |
| MGC | Myasthenia Gravis Composite |
| MGFA | Myasthenia Gravis Foundation of America |
| MGTX | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone |
| mITT | Modified intention-to-treat |
| mRNA | Messenger ribonucleic acid |
| MS-DRG | Medicare severity diagnosis-related group |
| mTOR | Mechanistic target of rapamycin |
| MuSK | Muscle-specific tyrosine kinase |
| NCI | National Cancer Institute |
| NHS | National Health Service |
| pDC | Plasmacytoid dendritic cell |
| PIS | Postintervention status |
| QALY | Quality-adjusted life-year |
| QMG | Quantitative Myasthenia Gravis |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNA | Ribonucleic acid |
| SAE | Serious adverse event |
| SD | Standard deviation |
| UK | United Kingdom |
| US | United States |
| USD | U.S. dollars |